thalidomide has been researched along with Cancer of Kidney in 57 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this pilot study a bone-targeted regimen combining zoledronate, thalidomide, and interferon-gamma was well tolerated and might provide clinical benefit for a small subset of patients with renal cell carcinoma and bone metastases." | 5.12 | Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. ( Do, KA; Jonasch, E; Lin, P; Lin, SH; Mathew, P; Pagliaro, LC; Rhines, L; Siefker-Radtke, A; Tannir, N; Tibbs, R; Tu, SM, 2006) |
| " The MTD was found to be continuous dosing of lenalidomide 10 mg/day plus sunitinib 37." | 2.79 | A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. ( Beck, R; Burris, HA; Fandi, A; Garcia, JA; Infante, JR; Jungnelius, U; Li, S; Redman, B; Rini, B, 2014) |
| "Thalidomide was continued until the time of disease progression or documented severe toxicity." | 2.77 | Low-dose thalidomide in patients with metastatic renal cell carcinoma. ( Hashmi, A; Masood, R; Naimatullah, N; Qayyum, A; Tunio, MA, 2012) |
| "Thalidomide treatment, however, was not an independent predictor of recurrence or cancer-specific mortality." | 2.74 | Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. ( Jonasch, E; Lozano, M; Margulis, V; Matin, SF; Shen, Y; Swanson, DA; Tamboli, P; Tannir, N; Wood, CG, 2009) |
| "Thalidomide has been described as inhibitor of the fibroblast growth factor (FGF) and the vascular endothelial growth factor (VEGF)." | 2.74 | Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. ( Brossart, P; Gorschlüter, M; Hauser, S; Kim, Y; Kraemer, A; Müller, SC; Schmidt-Wolf, IG, 2009) |
| "Disease progression was observed in 14 (45%) patients." | 2.73 | Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. ( Amato, RJ; Malya, R; Rawat, A, 2008) |
| "Treatments for refractory metastatic renal cell cancer (RCC) are limited." | 2.73 | Lenalidomide therapy for metastatic renal cell carcinoma. ( Amato, RJ; Hernandez-McClain, J; Khan, M; Saxena, S, 2008) |
| "Patients with proven metastatic renal cell carcinoma were examined prospectively with functional CT." | 2.73 | CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. ( Charnsangavej, C; Daliani, D; Faria, SC; Hess, KR; Ng, CS; Phongkitkarun, S; Szejnfeld, J, 2007) |
| "Gemcitabine was given by intravenous administration over 30 min on day 1, week 1 and day 8, week 2." | 2.73 | A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma. ( Amato, RJ; Khan, M, 2008) |
| "Lenalidomide (CC-5013) is a structural derivative of thalidomide, with antiangiogenic and immunomodulatory effects." | 2.73 | Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. ( Bacik, J; DeLuca, J; Ishill, N; Kondagunta, GV; Motzer, RJ; Patel, PH; Russo, P; Schwartz, L, 2008) |
| "Thalidomide in combination with IL-2 is tolerable and can produce durable, active responses in patients with MRCC." | 2.72 | Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. ( Amato, RJ; Morgan, M; Rawat, A, 2006) |
| "Thalidomide was started at 100 mg/d orally (PO) and escalated by 100 mg/d every 2 weeks to the maximum dose of 400 mg/d." | 2.72 | Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. ( A'Hern, R; Beirne, DA; Eisen, T; Gore, ME; Hancock, BW; James, MG; Lee, CP; Mak, I; Patel, PM; Pyle, L; Selby, PJ; Steeds, S, 2006) |
| "Lenalidomide (LEN) is a structural and functional analogue of thalidomide that has demonstrated enhanced immunomodulatory properties and a more favorable toxicity profile." | 2.72 | Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. ( Baz, RC; Bukowski, RM; Choueiri, TK; Dreicer, R; Elson, P; Garcia, JA; Jinks, HA; Mekhail, TM; Rini, BI; Thakkar, SG, 2006) |
| "Thalidomide was first given 100 mg/d for 1 week and 300 mg/d thereafter." | 2.71 | Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. ( Ahtinen, H; Bono, P; Hernberg, M; joensuu, H; Mäenpää, H; Virkkunen, P, 2003) |
| "Thalidomide was started at 100 mg/day for 2 weeks and then escalated 200 mg every 2 weeks to 1000 mg or until grade 3-4 toxicity developed." | 2.71 | Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. ( Brinkley, W; Clark, PE; Das, S; Hall, MC; Lovato, JF; Miller, A; Patton, SE; Ridenhour, KP; Stindt, D; Torti, FM, 2004) |
| "Oral thalidomide was started at 200 mg/day and escalated after 2 days to 400 mg/day at week 0." | 2.71 | Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma. ( Hegele, A; Heidenreich, A; Hofmann, R; Ohlmann, CH; Olbert, P; Schrader, AJ; Varga, Z; von Knobloch, R, 2005) |
| "Metastatic renal cell cancer is one of the immuno-sensitive tumors." | 2.71 | Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. ( Bex, A; Boogerd, W; de Gast, GC; Dewit, L; Haanen, JB; Kerst, JM; Mallo, H; Teertstra, HJ, 2005) |
| "Thalidomide was given daily at a starting dose of 400 mg, followed by a 400 mg increment to 800 mg and then to 1200 mg with 6-12 weeks at each dose level." | 2.70 | Phase II trial of thalidomide in renal-cell carcinoma. ( Angevin, E; Couanet, D; Dupouy, N; Escudier, B; Garofano, A; Laplanche, A; Lassau, N; Leborgne, S; Leboulaire, C; Mesrati, F, 2002) |
| "The highly vascular nature of renal cell carcinoma (RCC) suggests that angiogenesis inhibition may be therapeutic for patients with this disease." | 2.70 | A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. ( Amato, R; Daliani, DD; Oliva, R; Pagliaro, L; Papandreou, CN; Perez, C; Thall, PF; Wang, X, 2002) |
| " The dose-response relationship, if any, of thalidomide for renal cell carcinoma is unclear." | 2.70 | A phase II study of thalidomide in advanced metastatic renal cell carcinoma. ( Damico, LA; Elias, L; Meng, G; Minor, DR; Monroe, D; Suryadevara, U, 2002) |
| "Treatment continued until disease progression or unacceptable toxicity were encountered." | 2.70 | The treatment of advanced renal cell cancer with high-dose oral thalidomide. ( Ahern, R; Benson, C; Bridle, H; Eisen, T; Gore, ME; Mak, I; Pyle, L; Sapunar, F; Smalley, K; Stebbing, J, 2001) |
| "In the United States, advanced kidney cancer accounts for over 12,000 deaths each year." | 2.43 | Promising systemic therapy for renal cell carcinoma. ( Cooney, MM; Remick, SC; Vogelzang, NJ, 2005) |
| "Thalidomide has significant neurotoxicity and its efficacy was not confirmed in recent studies." | 2.42 | Renal cell carcinoma: novel treatments for advanced disease. ( Heinzer, H; Huland, E, 2003) |
| "Thalidomide was first used in the late 1950s but it was withdrawn from the market in the 1960s for its notorious teratogenic effects." | 2.42 | The promise of thalidomide: evolving indications. ( Joglekar, S; Levin, M, 2004) |
| "Advanced kidney cancer accounts for over 12,000 deaths in the United States each year." | 2.42 | Novel agents for the treatment of advanced kidney cancer. ( Cooney, MM; Remick, SC; Vogelzang, NJ, 2004) |
| "Several promising approaches to the treatment of renal cancer have been developed over recent years." | 2.41 | [Metastatic kidney cancer: new therapeutic approaches]. ( Escudier, B; Mejean, A; Negrier, S; Oudard, S, 2002) |
| "Zoledronic acid was given to both patients by 15 minutes intravenous infusion followed by hemodialysis 24 hours later." | 1.35 | [Zoledronic acid for bone metastases due to advanced renal cell carcinoma under chronic hemodialysis--a report of two cases]. ( Arima, S; Hayakawa, K; Hoshinaga, K; Kusaka, M; Maruyama, T; Miyakawa, S; Mori, S; Sasaki, H; Shiroki, R, 2008) |
| "We present a patient with renal carcinoma of the left kidney who underwent laparoscopic extrafascial nephrectomy and adrenalectomy." | 1.33 | Major response and clinical benefit following third-line treatment for Bellini duct carcinoma. ( Balassy, C; Fakhrai, N; Haitel, A; Schmidinger, M; Zielinski, CC, 2005) |
| "Oral thalidomide was started at 200 mg/d and escalated after two days to 400 mg/d at week 0." | 1.33 | [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study]. ( Hegele, A; Heidenreich, A; Hofmann, R; Olbert, P; Schrader, AJ; Varga, Z, 2006) |
| "Four patients with metastatic renal cell carcinoma and high serum levels of CRP and IL-6 who had experienced disease progression on IL-2 were retreated with the same IL-2 regimen combined with thalidomide 300 mg p." | 1.32 | Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. ( Ivgi, H; Kedar, I; Mermershtain, W, 2004) |
| "Thalidomide failed to inhibit the growth of xenograft tumours." | 1.31 | Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide. ( Douglas, ML; Hii, SI; Jonsson, JR; Nicol, DL; Reid, JL, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.75) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 50 (87.72) | 29.6817 |
| 2010's | 4 (7.02) | 24.3611 |
| 2020's | 2 (3.51) | 2.80 |
| Authors | Studies |
|---|---|
| Kaelin, WG | 1 |
| Amare, GG | 1 |
| Meharie, BG | 1 |
| Belayneh, YM | 1 |
| Rini, B | 1 |
| Redman, B | 1 |
| Garcia, JA | 2 |
| Burris, HA | 1 |
| Li, S | 1 |
| Fandi, A | 1 |
| Beck, R | 1 |
| Jungnelius, U | 1 |
| Infante, JR | 1 |
| Amato, RJ | 7 |
| Malya, R | 1 |
| Rawat, A | 3 |
| Hernandez-McClain, J | 1 |
| Saxena, S | 1 |
| Khan, M | 2 |
| Arima, S | 1 |
| Shiroki, R | 1 |
| Mori, S | 1 |
| Maruyama, T | 1 |
| Sasaki, H | 1 |
| Kusaka, M | 1 |
| Miyakawa, S | 1 |
| Hayakawa, K | 1 |
| Hoshinaga, K | 1 |
| Harshman, LC | 1 |
| Li, M | 1 |
| Srinivas, S | 2 |
| Margulis, V | 1 |
| Matin, SF | 1 |
| Tannir, N | 2 |
| Tamboli, P | 1 |
| Shen, Y | 1 |
| Lozano, M | 1 |
| Swanson, DA | 1 |
| Jonasch, E | 2 |
| Wood, CG | 1 |
| Chen, Q | 1 |
| Lin, RB | 1 |
| Ye, YB | 1 |
| Fan, NF | 1 |
| Guo, ZQ | 1 |
| Zhou, ZF | 1 |
| Wang, XJ | 1 |
| Chen, MS | 1 |
| Chen, SP | 1 |
| Li, JY | 1 |
| Kraemer, A | 1 |
| Hauser, S | 1 |
| Kim, Y | 1 |
| Gorschlüter, M | 1 |
| Müller, SC | 1 |
| Brossart, P | 1 |
| Schmidt-Wolf, IG | 1 |
| Kawada, H | 1 |
| Arima, N | 1 |
| Tunio, MA | 1 |
| Hashmi, A | 1 |
| Qayyum, A | 1 |
| Naimatullah, N | 1 |
| Masood, R | 1 |
| Escudier, B | 2 |
| Lassau, N | 1 |
| Couanet, D | 1 |
| Angevin, E | 1 |
| Mesrati, F | 1 |
| Leborgne, S | 1 |
| Garofano, A | 1 |
| Leboulaire, C | 1 |
| Dupouy, N | 1 |
| Laplanche, A | 1 |
| Daliani, DD | 1 |
| Papandreou, CN | 1 |
| Thall, PF | 1 |
| Wang, X | 1 |
| Perez, C | 1 |
| Oliva, R | 1 |
| Pagliaro, L | 1 |
| Amato, R | 2 |
| Desai, AA | 1 |
| Vogelzang, NJ | 3 |
| Rini, BI | 2 |
| Ansari, R | 1 |
| Krauss, S | 1 |
| Stadler, WM | 1 |
| Raje, N | 1 |
| Anderson, KC | 1 |
| Minor, DR | 1 |
| Monroe, D | 1 |
| Damico, LA | 1 |
| Meng, G | 1 |
| Suryadevara, U | 1 |
| Elias, L | 1 |
| Negrier, S | 1 |
| Mejean, A | 1 |
| Oudard, S | 1 |
| Whang, YE | 1 |
| Godley, PA | 1 |
| Schwartz, LH | 1 |
| Mazumdar, M | 1 |
| Wang, L | 1 |
| Smith, A | 1 |
| Marion, S | 1 |
| Panicek, DM | 1 |
| Motzer, RJ | 2 |
| Hernberg, M | 1 |
| Virkkunen, P | 1 |
| Bono, P | 1 |
| Ahtinen, H | 1 |
| Mäenpää, H | 1 |
| joensuu, H | 1 |
| Huland, E | 1 |
| Heinzer, H | 1 |
| Kedar, I | 1 |
| Mermershtain, W | 1 |
| Ivgi, H | 1 |
| Joglekar, S | 1 |
| Levin, M | 1 |
| Clark, PE | 1 |
| Hall, MC | 1 |
| Miller, A | 1 |
| Ridenhour, KP | 1 |
| Stindt, D | 1 |
| Lovato, JF | 1 |
| Patton, SE | 1 |
| Brinkley, W | 1 |
| Das, S | 1 |
| Torti, FM | 1 |
| Gordon, MS | 1 |
| Schrader, AJ | 3 |
| Heidenreich, A | 2 |
| Hegele, A | 2 |
| Olbert, P | 2 |
| Ohlmann, CH | 1 |
| Varga, Z | 3 |
| von Knobloch, R | 1 |
| Hofmann, R | 3 |
| Staehler, M | 1 |
| Rohrmann, K | 1 |
| Bachmann, A | 1 |
| Zaak, D | 1 |
| Stief, CG | 1 |
| Siebels, M | 1 |
| Kerst, JM | 1 |
| Bex, A | 1 |
| Mallo, H | 1 |
| Dewit, L | 1 |
| Haanen, JB | 1 |
| Boogerd, W | 1 |
| Teertstra, HJ | 1 |
| de Gast, GC | 1 |
| Fakhrai, N | 1 |
| Haitel, A | 1 |
| Balassy, C | 1 |
| Zielinski, CC | 1 |
| Schmidinger, M | 1 |
| Guardino, AE | 1 |
| Cooney, MM | 2 |
| Remick, SC | 2 |
| Pfoertner, S | 1 |
| Goelden, U | 1 |
| Buer, J | 1 |
| Morgan, M | 1 |
| Lee, CP | 1 |
| Patel, PM | 1 |
| Selby, PJ | 1 |
| Hancock, BW | 1 |
| Mak, I | 2 |
| Pyle, L | 2 |
| James, MG | 1 |
| Beirne, DA | 1 |
| Steeds, S | 1 |
| A'Hern, R | 1 |
| Gore, ME | 3 |
| Eisen, T | 2 |
| Pagliaro, LC | 1 |
| Mathew, P | 1 |
| Siefker-Radtke, A | 1 |
| Rhines, L | 1 |
| Lin, P | 1 |
| Tibbs, R | 1 |
| Do, KA | 1 |
| Lin, SH | 1 |
| Tu, SM | 1 |
| Vaishampayan, UN | 1 |
| Heilbrun, LK | 1 |
| Shields, AF | 1 |
| Lawhorn-Crews, J | 1 |
| Baranowski, K | 1 |
| Smith, D | 1 |
| Flaherty, LE | 1 |
| Choueiri, TK | 1 |
| Dreicer, R | 1 |
| Elson, P | 1 |
| Thakkar, SG | 1 |
| Baz, RC | 1 |
| Mekhail, TM | 1 |
| Jinks, HA | 1 |
| Bukowski, RM | 1 |
| Miller, K | 1 |
| Patil, S | 1 |
| Schwarer, A | 1 |
| McLean, C | 1 |
| Faria, SC | 1 |
| Ng, CS | 1 |
| Hess, KR | 1 |
| Phongkitkarun, S | 1 |
| Szejnfeld, J | 1 |
| Daliani, D | 1 |
| Charnsangavej, C | 1 |
| Stein, EM | 1 |
| Rivera, C | 1 |
| Maisey, N | 1 |
| Patel, PH | 1 |
| Kondagunta, GV | 1 |
| Schwartz, L | 1 |
| Ishill, N | 1 |
| Bacik, J | 1 |
| DeLuca, J | 1 |
| Russo, P | 1 |
| Mohammad, T | 1 |
| Eisen, TG | 3 |
| Stebbing, J | 1 |
| Benson, C | 1 |
| Smalley, K | 1 |
| Bridle, H | 1 |
| Sapunar, F | 1 |
| Ahern, R | 1 |
| Nathan, PD | 2 |
| Douglas, ML | 1 |
| Reid, JL | 1 |
| Hii, SI | 1 |
| Jonsson, JR | 1 |
| Nicol, DL | 1 |
| Roe, FJ | 1 |
| Walters, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Lenalidomide in Combination With Sunitinib in Subjects With Advanced or Metastatic Renal Cell Carcinoma[NCT00975806] | Phase 1/Phase 2 | 16 participants (Actual) | Interventional | 2009-09-01 | Terminated (stopped due to MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.) | ||
| Phase II Trial of CC-5013 in Patients With Advanced Renal Cell Carcinoma With Either No Prior Treatment or One Prior Treatment Regimen[NCT00096525] | Phase 2 | 0 participants | Interventional | 2004-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The MTD of lenalidomide in combination with sunitinib was defined as the highest dose level at which no more than 1 out of 6 participants experienced a dose limiting toxicity (DLT). Dose limiting toxicities were:~• Inability to deliver Lenalidomide in Cycle 1 due to a drug-related toxicity resulting in:~Grade (GR) 3 or 4 non-hematological toxicity lasting for ≥ 14 days~Febrile neutropenia~Gr 4 neutropenia lasting for ≥ 7 days~Gr 4 thrombocytopenia The occurrence of one of the above drug-related toxicities resulting in a clinical and/or laboratory assessment being done within 7 days following the initial finding to examine the participants for resolution of the toxicity. Lack of resolution of the toxicities was considered a DLT.~If ≤ 7 doses of lenalidomide or Sunitinib were missed in Cycle 1 due to non-drug related event, the participant data was to be included in the evaluation of dose escalation." (NCT00975806)
Timeframe: Within 21 days of first dose of treatment
| Intervention | mg (Number) |
|---|---|
| Cohort F: Lenalidomide 10mg and Sunitinib 37.5mg | 10 |
"Tumor response was evaluated every 3 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response was evaluated using the Response Criteria Evaluation in Solid Tumors (RECIST 1.1) criteria:~Treatment response includes both complete response and partial response~Complete response-disappearance of all lesions~Partial response-30% decrease in the sum of diameters of target lesions from baseline~Stable disease-neither shrinkage nor increase of lesions~Progressive Disease-20% increase in the sum of diameters of target lesions from nadir" (NCT00975806)
Timeframe: Every 3 cycles; up to month 25
| Intervention | participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | |
| Cohort A: Lenalidomide 10mg and Sunitinib 37.5 mg | 0 | 1 | 1 |
| Cohort F: Lenalidomide 10mg and Sunitinib 37.5mg | 0 | 0 | 3 |
| Cohort G: Lenalidomide 15mg and Sunitinib 37.5mg | 0 | 0 | 3 |
Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participants health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute [NCI] Common Toxicity Criteria for Adverse Events [CTCAE], Version 4.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death (NCT00975806)
Timeframe: First day of study drug to within 28 days after the last dose of the last study drug; The duration of exposure to lenalidomide and sunitinib was 7.0 to 327 and 7.0 to 328 days respectively
| Intervention | participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Participants with at least 1 TEAE | Participants with at least 1 serious TEAE | ≥ 1 TEAE leading to stopping lenalidomide | ≥ 1 TEAE leading to stopping sunitinib | ≥ 1 TEAE -> dose reduction/interrruption of Len | ≥ 1 TEAE dose reduction/interrruption of Sunitinib | Participants with ≥1 TEAE related to lenalidomide | Participants with ≥1 TEAE related to Sunitinib | ≥ 1 NCI CTC Gr 3 or higher TEAE | ≥ 1 NCI CTC Gr 3 or higher related to lenalidomide | ≥ 1 NCI CTC Gr 3 or higher related to Sunitinib | ≥ 1 serious TEAE related to lenalidomide | ≥ 1 serious TEAE related to sunitinib | |
| Cohort A: Lenalidomide 10mg and Sunitinib 37.5 mg | 5 | 3 | 2 | 2 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 2 | 1 |
| Cohort F: Lenalidomide 10mg and Sunitinib 37.5mg | 7 | 4 | 2 | 2 | 6 | 5 | 7 | 7 | 6 | 5 | 5 | 2 | 2 |
| Cohort G: Lenalidomide 15mg and Sunitinib 37.5mg | 4 | 2 | 2 | 2 | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 0 | 2 |
15 reviews available for thalidomide and Cancer of Kidney
| Article | Year |
|---|---|
A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide.
Topics: Cytokines; Drug Repositioning; Female; Humans; Immunosuppressive Agents; Infant, Newborn; Kidney Neo | 2021 |
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; | 2012 |
Thalidomide and immunomodulatory drugs as cancer therapy.
Topics: Adjuvants, Immunologic; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Humans; Immun | 2002 |
[Metastatic kidney cancer: new therapeutic approaches].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Kidney Neoplasms; Neoplasm Metastasis; Neopl | 2002 |
Renal cell carcinoma.
Topics: Adult; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Child; Child, Preschool; Clinical Trials as To | 2003 |
Thalidomide therapy for renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cape | 2003 |
Renal cell carcinoma: novel treatments for advanced disease.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Cancer Vaccines; Carcinoma, Renal Cell; Combined Moda | 2003 |
The promise of thalidomide: evolving indications.
Topics: Cachexia; Carcinoma, Renal Cell; Clinical Trials as Topic; Erythema Nodosum; Graft vs Host Disease; | 2004 |
Novel antiangiogenic therapies for renal cell cancer.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Enzyme Inhibitors; Humans; Kidney Neoplasms; Matrix | 2004 |
Therapeutic approaches in metastatic renal cell carcinoma.
Topics: Adrenalectomy; Angiogenesis Inhibitors; Bone Marrow Transplantation; Bone Neoplasms; Cancer Vaccines | 2005 |
Promising systemic therapy for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2005 |
Novel agents for the treatment of advanced kidney cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2004 |
Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Car | 2006 |
Thalidomide in solid tumors: the London experience.
Topics: Adult; Angiogenesis Inhibitors; Breast Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II a | 2000 |
The biological treatment of renal-cell carcinoma and melanoma.
Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Hematopoietic Stem Cell Transplantation; Hu | 2002 |
27 trials available for thalidomide and Cancer of Kidney
| Article | Year |
|---|---|
A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2014 |
Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Constipation; Di | 2008 |
Lenalidomide therapy for metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression | 2008 |
The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Renal | 2008 |
Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Femal | 2009 |
Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycyt | 2009 |
Low-dose thalidomide in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Protocols; Carcinoma, Renal Cell; Disease Progr | 2012 |
Phase II trial of thalidomide in renal-cell carcinoma.
Topics: Adult; Age Factors; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Ren | 2002 |
A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Surv | 2002 |
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2002 |
A phase II study of thalidomide in advanced metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Constipation; Disorders of Excessive Somnolence; Endothelial Gro | 2002 |
Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug | 2003 |
Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 2004 |
Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modalit | 2005 |
Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; | 2005 |
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Ca | 2006 |
A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Double-Blin | 2005 |
Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2006 |
Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinoma, R | 2006 |
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neopla | 2006 |
Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcino | 2007 |
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Imm | 2006 |
CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Fe | 2007 |
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2008 |
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kid | 2008 |
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car | 2008 |
The treatment of advanced renal cell cancer with high-dose oral thalidomide.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Constipation; Cyt | 2001 |
15 other studies available for thalidomide and Cancer of Kidney
| Article | Year |
|---|---|
THE JEREMIAH METZGER LECTURE:VON HIPPEL-LINDAU DISEASE: INSIGHTS INTO OXYGEN SENSING, CANCER AND DRUGGING THE UNDRUGGABLE.
Topics: Carcinoma, Renal Cell; Humans; Hypoxia; Kidney Neoplasms; Ligases; Oxygen; Prolyl Hydroxylases; Thal | 2022 |
[Zoledronic acid for bone metastases due to advanced renal cell carcinoma under chronic hemodialysis--a report of two cases].
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Carcinoma, Renal Cell; Chronic Dise | 2008 |
The combined administration of partially HLA-matched irradiated allogeneic lymphocytes and thalidomide in advanced renal-cell carcinoma: a case report.
Topics: Carcinoma, Renal Cell; Combined Modality Therapy; Graft vs Host Disease; Histocompatibility Testing; | 2010 |
Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression | 2003 |
Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy.
Topics: Adult; C-Reactive Protein; Carcinoma, Renal Cell; Female; Humans; Interleukin-2; Interleukin-6; Kidn | 2004 |
Major response and clinical benefit following third-line treatment for Bellini duct carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cispla | 2005 |
[Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Pro | 2006 |
[Therapy sequence for renal cell carcinoma--new aspects!].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Combined M | 2007 |
Urinary cytology in multiple myeloma.
Topics: Acute Kidney Injury; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Fat | 2008 |
Transient thyroiditis after treatment with lenalidomide in a patient with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Humans; Kidne | 2007 |
Antitumor necrosis factor (TNF-a) antibodies in the treatment of renal cell cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as T | 2007 |
Thalidomide for recurrent renal-cell cancer in a 40-year-old man.
Topics: Adenocarcinoma, Clear Cell; Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Therapy, Com | 2000 |
Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Humans; Interferon alpha-2; I | 2002 |
Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Division; Drug Resistance, Neoplasm; H | 2002 |
Sensitivity of newborn mice to carcinogenic agents.
Topics: Adenocarcinoma; Adenoma; Animals; Animals, Newborn; Benz(a)Anthracenes; Carcinogens; Carcinoma, Hepa | 1968 |